Back to Search Start Over

Role of protective stoma after primary anastomosis for generalized peritonitis due to perforated diverticulitis—DIVERTI 2 (a prospective multicenter randomized trial): rationale and design (nct04604730)

Authors :
Jean Pinson
Jean-Jacques Tuech
Mehdi Ouaissi
Murielle Mathonnet
François Mauvais
Estelle Houivet
Elie Lacroix
Julie Rondeaux
Charles Sabbagh
Valérie Bridoux
DESSAIVRE, Louise
Interfaces, Traitements, Organisation et Dynamique des Systèmes (ITODYS (UMR_7086))
Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND)
Université de Rouen Normandie (UNIROUEN)
Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
EA4245 - Transplantation, Immunologie, Inflammation [Tours] (T2i)
Université de Tours (UT)
Université de Limoges (UNILIM)
Chirurgie digestive [CHU Amiens]
CHU Amiens-Picardie
Simplification des soins chez les patients complexes - UR UPJV 7518 (SSPC)
Université de Picardie Jules Verne (UPJV)
Unité de biostatistiques [CHU Rouen]
CHU Rouen
Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN)
Normandie Université (NU)
Centre de recherche en épidémiologie et santé des populations (CESP)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Endothélium, valvulopathies et insuffisance cardiaque (EnVI)
Nouvelles Cibles Pharmacologiques de la Protection Endothéliale et de l'Insuffisance Cardiaque (EnVI)
Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau (ADEN)
Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB)
Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN)
Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institute for Research and Innovation in Biomedicine (IRIB)
Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
UNIROUEN - UFR Santé (UNIROUEN UFR Santé)
Normandie Université (NU)-Normandie Université (NU)
Service de chirurgie digestive [CHU Rouen]
Source :
BMC Surgery, BMC Surgery, 2022, 22 (1), pp.191. ⟨10.1186/s12893-022-01589-w⟩
Publication Year :
2022
Publisher :
HAL CCSD, 2022.

Abstract

Background Traditionally, patients with peritonitis Hinchey III and IV due to perforated diverticulitis were treated with Hartmann’s procedure. In the past decade, resection and primary anastomosis have gained popularity over Hartmann’s procedure and recent guidelines recommend Hartmann’s procedure in two situations only: critically ill patients and in selected patients with multiple comorbidity (at high risk of complications). The protective stoma (PS) is recommended after resection with primary anastomosis, however its interest has never been studied. The aim of this trial is to define the role of systematic PS after resection and primary anastomosis for peritonitis Hinchey III and IV due to perforated diverticulitis. Methods/design This DIVERTI 2 trial is a multicenter, randomized, controlled, superiority trial comparing resection and primary anastomosis with (control group) or without (experimental group) PS in patients with peritonitis Hinchey III and IV due to perforated diverticulitis. Primary endpoint is the overall 1 year morbidity according to the Clavien–Dindo classification of surgical complications. All complications occurring during hospitalization will be collected. Late complications occurring after hospitalization will be collected during follow-up. In order to obtain 80% power for a difference given by respective main probabilities of 67% and 47% in the protective stoma and no protective stoma groups respectively, with a two-sided type I error of 5%, 96 patients will have to be included in each group, hence 192 patients overall. Expecting a 5% rate of patients not assessable for the primary end point (lost to follow-up), 204 patients will be enrolled. Secondary endpoints are postoperative mortality, unplanned reinterventions, incisional surgical site infection (SSI), organ/space SSI, wound disruption, anastomotic leak, operating time, length of hospital stay, stoma at 1 year after initial surgery, quality of life, costs and quality-adjusted life years (QALYs). Discussion The DIVERTI 2 trial is a prospective, multicenter, randomized, study to define the best strategy between PS and no PS in resection and primary anastomosis for patients presenting with peritonitis due to perforated diverticulitis. Trial registration ClinicalTrial.gov: NCT04604730 date of registration October 27, 2020. https://clinicaltrials.gov/ct2/show/NCT04604730?recrs=a&cond=Diverticulitis&draw=2&rank=12.

Details

Language :
English
ISSN :
14712482
Database :
OpenAIRE
Journal :
BMC Surgery, BMC Surgery, 2022, 22 (1), pp.191. ⟨10.1186/s12893-022-01589-w⟩
Accession number :
edsair.doi.dedup.....a02f1320fb9fe7d911200855c44b12ab
Full Text :
https://doi.org/10.1186/s12893-022-01589-w⟩